Published in Cancer Weekly, January 27th, 2004
The RTist application, in conjunction with the Mirada/CTI REVEAL-MVS workstation platform, permits radiation oncologists and/or physicists to utilize the benefits from all imaging modalities during radiotherapy target delineation.
This capability allows the structural information from computed tomographic (CT) and magnetic resonance (MR) images to be combined with the functional information from positron emission tomographic (PET) and SPECT studies. These...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.